Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 45 | 2019 | 185 | 7.830 |
Why?
|
| Neurons | 39 | 2019 | 394 | 4.980 |
Why?
|
| Memory | 22 | 2017 | 187 | 3.610 |
Why?
|
| Action Potentials | 33 | 2019 | 174 | 3.370 |
Why?
|
| Models, Neurological | 32 | 2019 | 115 | 3.270 |
Why?
|
| Psychomotor Performance | 12 | 2018 | 97 | 2.240 |
Why?
|
| Nerve Net | 16 | 2019 | 115 | 2.170 |
Why?
|
| Cannabinoids | 10 | 2017 | 39 | 2.020 |
Why?
|
| Memory, Short-Term | 9 | 2018 | 59 | 1.740 |
Why?
|
| Prefrontal Cortex | 8 | 2014 | 69 | 1.690 |
Why?
|
| Animals | 69 | 2019 | 7297 | 1.370 |
Why?
|
| Rats | 39 | 2017 | 1604 | 1.350 |
Why?
|
| Receptor, Cannabinoid, CB1 | 9 | 2015 | 51 | 1.310 |
Why?
|
| Nonlinear Dynamics | 26 | 2019 | 51 | 1.280 |
Why?
|
| CA1 Region, Hippocampal | 16 | 2017 | 26 | 1.260 |
Why?
|
| Electrodes, Implanted | 12 | 2018 | 41 | 1.220 |
Why?
|
| Macaca mulatta | 17 | 2019 | 322 | 1.210 |
Why?
|
| Endocannabinoids | 5 | 2011 | 34 | 1.180 |
Why?
|
| Rats, Long-Evans | 21 | 2017 | 72 | 1.150 |
Why?
|
| CA3 Region, Hippocampal | 14 | 2017 | 16 | 1.150 |
Why?
|
| Behavior, Animal | 13 | 2017 | 264 | 0.810 |
Why?
|
| Cognition | 8 | 2016 | 524 | 0.790 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 41 | 0.740 |
Why?
|
| Learning | 4 | 2013 | 75 | 0.670 |
Why?
|
| Synaptic Transmission | 6 | 2016 | 113 | 0.650 |
Why?
|
| Pyrazoles | 9 | 2015 | 64 | 0.650 |
Why?
|
| Pyramidal Cells | 3 | 2011 | 15 | 0.640 |
Why?
|
| Mental Recall | 1 | 2018 | 52 | 0.640 |
Why?
|
| Neural Pathways | 8 | 2014 | 97 | 0.620 |
Why?
|
| Male | 37 | 2019 | 17768 | 0.610 |
Why?
|
| Reward | 2 | 2010 | 63 | 0.600 |
Why?
|
| Computer Simulation | 14 | 2019 | 202 | 0.590 |
Why?
|
| Benzoxazines | 9 | 2015 | 20 | 0.560 |
Why?
|
| Morpholines | 9 | 2015 | 34 | 0.550 |
Why?
|
| Naphthalenes | 9 | 2015 | 39 | 0.550 |
Why?
|
| Journalism | 1 | 2015 | 1 | 0.520 |
Why?
|
| Piperidines | 9 | 2015 | 125 | 0.520 |
Why?
|
| Electric Stimulation | 7 | 2013 | 102 | 0.520 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 81 | 0.520 |
Why?
|
| Neurosciences | 1 | 2015 | 8 | 0.520 |
Why?
|
| Glutamic Acid | 2 | 2014 | 46 | 0.470 |
Why?
|
| Ceramics | 1 | 2013 | 4 | 0.460 |
Why?
|
| Memory Disorders | 4 | 2016 | 61 | 0.440 |
Why?
|
| Biofeedback, Psychology | 1 | 2012 | 11 | 0.430 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 36 | 0.430 |
Why?
|
| Information Storage and Retrieval | 1 | 2012 | 24 | 0.430 |
Why?
|
| Reaction Time | 5 | 2010 | 121 | 0.410 |
Why?
|
| Cortical Synchronization | 1 | 2011 | 3 | 0.410 |
Why?
|
| Behavior | 2 | 2010 | 29 | 0.400 |
Why?
|
| Cognition Disorders | 4 | 2012 | 389 | 0.400 |
Why?
|
| Sleep Deprivation | 2 | 2007 | 7 | 0.390 |
Why?
|
| Cell Movement | 1 | 2010 | 161 | 0.360 |
Why?
|
| Neurophysiology | 1 | 2009 | 9 | 0.360 |
Why?
|
| Microelectrodes | 4 | 2016 | 16 | 0.340 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2019 | 33 | 0.330 |
Why?
|
| Neural Inhibition | 3 | 2017 | 27 | 0.330 |
Why?
|
| Serial Learning | 1 | 2008 | 2 | 0.320 |
Why?
|
| Brain | 7 | 2018 | 930 | 0.320 |
Why?
|
| Sympathomimetics | 1 | 2007 | 4 | 0.320 |
Why?
|
| Neuropeptides | 1 | 2007 | 18 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 72 | 0.310 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 18 | 0.300 |
Why?
|
| Task Performance and Analysis | 5 | 2017 | 51 | 0.300 |
Why?
|
| Receptors, Drug | 3 | 2003 | 14 | 0.300 |
Why?
|
| Deep Brain Stimulation | 4 | 2015 | 49 | 0.300 |
Why?
|
| Brain Injuries | 2 | 2018 | 94 | 0.290 |
Why?
|
| Receptors, Cannabinoid | 5 | 2011 | 26 | 0.290 |
Why?
|
| Signal Processing, Computer-Assisted | 5 | 2014 | 33 | 0.290 |
Why?
|
| Brain Mapping | 4 | 2010 | 182 | 0.290 |
Why?
|
| Prosthesis Design | 5 | 2016 | 87 | 0.280 |
Why?
|
| Electrophysiology | 3 | 2012 | 66 | 0.270 |
Why?
|
| Epilepsy | 2 | 2017 | 59 | 0.270 |
Why?
|
| Postural Balance | 2 | 2016 | 160 | 0.260 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 141 | 0.250 |
Why?
|
| Photic Stimulation | 3 | 2014 | 155 | 0.250 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 12 | 0.250 |
Why?
|
| Humans | 24 | 2019 | 29013 | 0.240 |
Why?
|
| Cocaine | 4 | 2012 | 262 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 641 | 0.240 |
Why?
|
| Drug Tolerance | 2 | 2003 | 36 | 0.240 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Lidocaine | 1 | 2003 | 17 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 32 | 0.230 |
Why?
|
| Marijuana Abuse | 1 | 2003 | 18 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 109 | 0.220 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 92 | 0.220 |
Why?
|
| Motor Activity | 5 | 2015 | 310 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Executive Function | 2 | 2013 | 54 | 0.220 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 74 | 0.220 |
Why?
|
| Random Allocation | 2 | 2013 | 212 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2014 | 747 | 0.210 |
Why?
|
| Analysis of Variance | 4 | 2014 | 454 | 0.200 |
Why?
|
| Arachidonic Acids | 2 | 2011 | 23 | 0.200 |
Why?
|
| Carbamates | 2 | 2011 | 14 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 56 | 0.200 |
Why?
|
| Benzamides | 2 | 2011 | 54 | 0.200 |
Why?
|
| Algorithms | 9 | 2018 | 461 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 172 | 0.190 |
Why?
|
| Acetylcholine | 2 | 2010 | 47 | 0.190 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Electrophysiological Phenomena | 3 | 2013 | 28 | 0.170 |
Why?
|
| Calcium | 3 | 2013 | 296 | 0.170 |
Why?
|
| Fibronectins | 1 | 2018 | 34 | 0.160 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 71 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 95 | 0.160 |
Why?
|
| Seizures | 1 | 2018 | 61 | 0.160 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 145 | 0.150 |
Why?
|
| Likelihood Functions | 3 | 2013 | 38 | 0.150 |
Why?
|
| Time Factors | 5 | 2019 | 1997 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 103 | 0.150 |
Why?
|
| Synapses | 1 | 2017 | 85 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 48 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2017 | 67 | 0.140 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 84 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 226 | 0.140 |
Why?
|
| Baclofen | 2 | 2013 | 12 | 0.140 |
Why?
|
| Biological Clocks | 1 | 2015 | 4 | 0.140 |
Why?
|
| Equipment Design | 4 | 2009 | 167 | 0.130 |
Why?
|
| Space Perception | 2 | 2007 | 26 | 0.130 |
Why?
|
| Pattern Recognition, Physiological | 1 | 2014 | 3 | 0.130 |
Why?
|
| Electrodes | 2 | 2013 | 16 | 0.130 |
Why?
|
| Probability Theory | 1 | 2014 | 1 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2015 | 48 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2015 | 68 | 0.130 |
Why?
|
| Glycine | 2 | 2013 | 25 | 0.130 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 10 | 0.130 |
Why?
|
| Sleep | 1 | 2015 | 84 | 0.120 |
Why?
|
| Neuroprotective Agents | 2 | 2005 | 20 | 0.120 |
Why?
|
| Spatial Behavior | 2 | 2013 | 9 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2015 | 159 | 0.120 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 87 | 0.120 |
Why?
|
| Monte Carlo Method | 3 | 2014 | 17 | 0.120 |
Why?
|
| User-Computer Interface | 2 | 2011 | 34 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 3 | 0.110 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2013 | 7 | 0.110 |
Why?
|
| Perception | 1 | 2013 | 92 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 73 | 0.110 |
Why?
|
| ROC Curve | 4 | 2014 | 148 | 0.110 |
Why?
|
| Information Theory | 1 | 2011 | 3 | 0.110 |
Why?
|
| Electroencephalography | 3 | 2018 | 71 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 34 | 0.100 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cell Communication | 1 | 2011 | 30 | 0.100 |
Why?
|
| Maze Learning | 2 | 2010 | 17 | 0.100 |
Why?
|
| Glycerides | 1 | 2011 | 13 | 0.100 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 19 | 0.100 |
Why?
|
| Injections | 1 | 2011 | 61 | 0.100 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2011 | 2 | 0.100 |
Why?
|
| Second Messenger Systems | 1 | 2011 | 6 | 0.100 |
Why?
|
| Wakefulness | 2 | 2015 | 22 | 0.100 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 18 | 0.100 |
Why?
|
| Macaca | 1 | 2010 | 25 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2011 | 225 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2010 | 45 | 0.090 |
Why?
|
| Telemetry | 1 | 2009 | 27 | 0.090 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 30 | 0.090 |
Why?
|
| Video Recording | 1 | 2009 | 51 | 0.090 |
Why?
|
| Decision Making | 1 | 2010 | 180 | 0.080 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 30 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2007 | 18 | 0.080 |
Why?
|
| Oxazoles | 2 | 2005 | 4 | 0.070 |
Why?
|
| Glucose | 1 | 2007 | 162 | 0.070 |
Why?
|
| Orientation | 1 | 2006 | 24 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 880 | 0.070 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 2 | 0.070 |
Why?
|
| Biomimetics | 1 | 2005 | 5 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 636 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2005 | 14 | 0.070 |
Why?
|
| Ryanodine | 1 | 2005 | 3 | 0.070 |
Why?
|
| Nootropic Agents | 1 | 2005 | 13 | 0.070 |
Why?
|
| Cytosol | 1 | 2004 | 25 | 0.060 |
Why?
|
| Methylmercury Compounds | 1 | 2004 | 7 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 28 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 35 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 724 | 0.060 |
Why?
|
| Hand | 1 | 2004 | 63 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 855 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2003 | 3 | 0.060 |
Why?
|
| Enzyme Activators | 1 | 2003 | 4 | 0.060 |
Why?
|
| omega-Conotoxin GVIA | 1 | 2003 | 4 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2003 | 7 | 0.060 |
Why?
|
| Interneurons | 1 | 2003 | 23 | 0.060 |
Why?
|
| GABA Agonists | 1 | 2003 | 2 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 12 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 77 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 76 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 49 | 0.060 |
Why?
|
| Receptors, GABA-B | 1 | 2003 | 13 | 0.060 |
Why?
|
| Models, Theoretical | 3 | 2012 | 126 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 51 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 53 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 162 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 246 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 129 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1422 | 0.050 |
Why?
|
| Cyclohexanols | 2 | 2015 | 20 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2007 | 160 | 0.050 |
Why?
|
| Dizocilpine Maleate | 2 | 2011 | 7 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2011 | 26 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 531 | 0.050 |
Why?
|
| Linear Models | 2 | 2013 | 425 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 481 | 0.050 |
Why?
|
| Adult | 2 | 2016 | 8391 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 76 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 2017 | 6 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2010 | 80 | 0.040 |
Why?
|
| Normal Distribution | 2 | 2009 | 12 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2017 | 30 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2017 | 41 | 0.040 |
Why?
|
| Computational Biology | 1 | 2017 | 86 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 98 | 0.040 |
Why?
|
| Gene Expression | 1 | 2018 | 332 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 118 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sleep, REM | 1 | 2015 | 6 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 980 | 0.030 |
Why?
|
| Oxotremorine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Resorcinols | 1 | 2013 | 6 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2013 | 7 | 0.030 |
Why?
|
| Concept Formation | 1 | 2013 | 2 | 0.030 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 15 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 9462 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 711 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2013 | 60 | 0.030 |
Why?
|
| Amplifiers, Electronic | 1 | 2012 | 1 | 0.030 |
Why?
|
| Analog-Digital Conversion | 1 | 2012 | 1 | 0.030 |
Why?
|
| Electronics | 1 | 2012 | 14 | 0.030 |
Why?
|
| Middle Aged | 1 | 2016 | 10805 | 0.030 |
Why?
|
| Computer Systems | 1 | 2011 | 12 | 0.030 |
Why?
|
| Primates | 1 | 2012 | 100 | 0.030 |
Why?
|
| Online Systems | 1 | 2011 | 13 | 0.030 |
Why?
|
| Ligands | 1 | 2011 | 81 | 0.030 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 120 | 0.020 |
Why?
|
| Phenylcarbamates | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 4 | 0.020 |
Why?
|
| Acetylcholinesterase | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 29 | 0.020 |
Why?
|
| Scopolamine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 11 | 0.020 |
Why?
|
| Feedback, Sensory | 1 | 2010 | 3 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 226 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2004 | 666 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 16 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 12 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2368 | 0.020 |
Why?
|
| Female | 1 | 2016 | 18114 | 0.020 |
Why?
|
| Swimming | 1 | 2007 | 7 | 0.020 |
Why?
|
| Microinjections | 1 | 2007 | 33 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 41 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 2007 | 19 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 378 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2006 | 4 | 0.020 |
Why?
|
| Dendrites | 1 | 2006 | 15 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 42 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2005 | 1 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2005 | 3 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2005 | 3 | 0.020 |
Why?
|
| Dantrolene | 1 | 2005 | 2 | 0.020 |
Why?
|
| Estrenes | 1 | 2005 | 2 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 5 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 12 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2005 | 45 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 18 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 49 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2005 | 40 | 0.020 |
Why?
|
| Cell Death | 1 | 2005 | 71 | 0.020 |
Why?
|
| Fetus | 1 | 2005 | 78 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 22 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 165 | 0.020 |
Why?
|
| Cannabis | 1 | 2004 | 18 | 0.010 |
Why?
|
| Research | 1 | 2004 | 72 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 33 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2002 | 24 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 155 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 799 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 172 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 320 | 0.010 |
Why?
|